Wenjia Guo

Wenjia Guo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
XZXiannian Zhang
Xiannian Zhang
LPLinna Peng
Linna Peng
YLYingying Luo
Yingying Luo
SZShaosen Zhang
Shaosen Zhang
YPYang Pu
Yang Pu
DLDongxin Lin
Dongxin Lin
Esophageal squamous-cell carcinoma (ESCC), one of the most prevalent and lethal malignant disease, has a complex but unknown tumor ecosystem. Here, we investigate the composition of ESCC tumors based on 208,659 single-cell transcriptomes derived from 60 individuals. We identify 8 common expression programs from malignant epithelial cells and discover 42 cell types, including 26 immune cell and 16 nonimmune stromal cell subtypes in the tumor microenvironment (TME), and analyse the interactions between cancer cells and other cells and the interactions among different cell types in the TME. Moreover, we link the cancer cell transcriptomes to the somatic mutations and identify several markers significantly associated with patients’ survival, which may be relevant to precision care of ESCC patients. These results reveal the immunosuppressive status in the ESCC TME and further our understanding of ESCC.

30 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYuan Lin
Yuan Lin
YLYingying Luo
Yingying Luo
YSYanxia Sun
Yanxia Sun
WGWenjia Guo
Wenjia Guo
XZXuan Zhao
Xuan Zhao
DLDongxin Lin
Dongxin Lin
Adenocarcinoma at the gastroesophageal junction (ACGEJ) has dismal clinical outcomes, and there are currently few specific effective therapies because of limited knowledge on its genomic and transcriptomic alterations. The present study investigates genomic and transcriptomic changes in ACGEJ from Chinese patients and analyzes their drug vulnerabilities and associations with the survival time. Here we show that the major genomic changes of Chinese ACGEJ patients are chromosome instability promoted tumorigenic focal copy-number variations and COSMIC Signature 17-featured single nucleotide variations. We provide a comprehensive profile of genetic changes that are potentially vulnerable to existing therapeutic agents and identify Signature 17-correlated IFN-α response pathway as a prognostic marker that might have practical value for clinical prognosis of ACGEJ. These findings further our understanding on the molecular biology of ACGEJ and may help develop more effective therapeutic strategies.

9 July 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
FLFuzhong Liu
Fuzhong Liu
JZJunfeng Zhang
Junfeng Zhang
XGXiaowei Gu
Xiaowei Gu
QGQiuyang Guo
Qiuyang Guo
WGWenjia Guo
Wenjia Guo
Triple‐negative breast cancer (TNBC) is often considered one of the most aggressive subtypes of breast cancer, characterized by a high recurrence rate and low overall survival (OS). It is notorious for posing challenges related to drug resistance. While there has been progress in TNBC research, the mechanisms underlying chemotherapy resistance in TNBC remain largely elusive. We collect single‐cell RNA sequencing (scRNA‐seq) data from five TNBC patients susceptible to chemotherapy and five resistant cases. Comprehensive analyses involving copy number variation (CNV), pseudotime trajectory, cell–cell interactions, pseudospace analysis, as well as transcription factor and functional enrichment are conducted specifically on macrophages and malignant cells. Furthermore, we performed validation experiments on clinical samples using multiplex immunofluorescence. We identified a subset of SPP1+ macrophages that secrete SPP1 signals interacting with CD44 on malignant cell surfaces, potentially activating the PDE3B pathway within malignant cells via the integrin pathway, leading to chemotherapy resistance. The abnormally enhanced SPP1 signal between macrophages and malignant cells may serve as a factor promoting chemotherapy resistance in TNBC patients. Therefore, SPP1+ macrophages could potentially serve as a therapeutic target to reduce chemotherapy resistance.

27 December 2024 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
DWDan Wang
Dan Wang
SZSicheng Zuo
Sicheng Zuo
JGJunshang Ge
Junshang Ge
HQHongke Qu
Hongke Qu
JWJie Wu
Jie Wu
CGCan Guo
Can Guo

26 February 2026 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
YSYuan-Dong Sun
Yuan-Dong Sun
XDXiao-Gang Dong
Xiao-Gang Dong
YCYi Chen
Yi Chen
JHJian-Jun Han
Jian-Jun Han
WGWenjia Guo
Wenjia Guo

12 August 2024 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
XCXun Chen
Xun Chen
PWPan Wu
Pan Wu
ZLZiqi Liu
Ziqi Liu
TLTiansheng Li
Tiansheng Li
JWJie Wu
Jie Wu
WXWei Xiong
Wei Xiong